Developing next generation kinase inhibitors for autoimmune disease & cancer.
*Molecular structure of TYK2 kinase (blue) and a prototype inhibitor (gold)
SCROLL DOWN
Welcome to Sareum.
Sareum is a clinical-stage small molecule company actively involved in developing next-generation kinase inhibitors to treat autoimmune diseases and cancer.
We recognise the crucial role of the TYK/JAK kinase cell signalling family in maintaining a healthy immune system, and our pipeline is primarily focused on this area of scientific and commercial interest.
About
Sareum.
We are committed to advancing molecules in the TYK2/JAK1 space. Our focus on this dual JAK kinase inhibition is due to the potential superior efficacy we believe this offers compared to agents targeting just one of these kinases.
Research &
development.
We are focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential.
Investor
relations.
View our share price, latest results and reports, regulatory news and sign up to email alerts.
15 January 2023
A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer.
Publication:
Clin Cancer Res
10 April 2021
A study of combinatorial growth inhibition, cell death and DNA damage repair caused by CHK1 inhibitor SRA737 and WEE1 inhibitor adavosertib in TP53 mutated cell line.
Publication:
AACR Annual Meeting
Latest developments.
Autoimmune – TYK2/JAK1 kinases
Cancer – TYK2/JAK1 kinases
TYK2/JAK1 – Viral Infections
Cancer – Chk1 kinase
Company highlight.
“We are encouraged by the preliminary data from the single ascending dose and food effect parts of the Phase 1a trial for SDC-1801, which support our confidence in the trial and the broader clinical strategy.”
Tim Mitchell PhD – Founder and CEO